Abstract 2066P
Background
This study aimed to assess the usefulness of ChatGPT and Perplexity's responses to frequently asked questions regarding the diagnosis and treatment of rectal cancer.
Methods
Both artificial intelligence systems were asked 20 questions covering disease risk factors, screening, symptoms, treatment, and treatment side effects. In accordance with the ESMO patient guides, the questions were posed in the order specified. According to ESMO patient guide recommendations, responses were graded as “appropriate,” “inappropriate,” or “insufficient.”
Results
While ChatGPT provided appropriate responses to 17 of the questions (85%), the responses to two questions (10%) were deemed inappropriate, and the response to one question (5%) was deemed insufficient. Nineteen (95%) of Perplexity's responses were deemed appropriate. It was determined that both artificial intelligence systems responded improperly to the nutrition question.
Conclusions
The study's findings indicate that ChatGPT and Perplexity provide patients with accurate information about rectal cancer. The accuracy rate of Perplexity was found to be higher than that of ChatGPT. It can be demonstrated that the benefit of Perplexity is that it displays the source for each piece of information. However, especially cancer patients require emotional and psychological assistance, and further research is required to determine the impact of these artificial intelligence systems on the patient's psychology. Moreover, given the complexity and individuality of medical care, AI chatbots should not be viewed as a replacement for medical professionals, but rather as a supplement that can help patients gain access to trustworthy information and support. Overall, this study contributes to the growing body of literature on AI chatbots and their potential use in cancer by highlighting both the advantages and disadvantages of these technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06